SNIPR BIOME initiates first-in-human clinical trial with SNIPR001
The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut
The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut
The MicroGEM Saliva test is the first point of care PCR saliva test for Covid-19 delivering results in minutes
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
New product line to address the challenge of restrictions on use of plastic straws
The data driven fertility company helps increase the success rate of fertility treatments
This partnership allows both companies to become first movers to bridge an inevitable gap with the largest organizations in the pharmaceutical, nutraceutical, cosmetic, and veterinary sectors
First of its kind interactive concept store ‘Brilliant Sound Galaxy (BSG)’ in the capital city
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Subscribe To Our Newsletter & Stay Updated